艾拓维医药

Aitowei Medicine is a China-based biotechnology company focused on the discovery and development of innovative small molecule drugs, with a particular emphasis on targeted protein degradation (PROTAC) technology. The company leverages its proprietary platform to design bifunctional molecules that recruit E3 ubiquitin ligases to specific disease-causing proteins, leading to their degradation. Aitowei's primary therapeutic focus is on oncology, specifically targeting hormone-driven cancers such as prostate and breast cancer. By addressing targets that are often considered undruggable by traditional inhibitors, the company aims to provide next-generation treatments for patients with resistant or refractory diseases.